On November 8, most eyes will be on the historic presidential contest between Hillary Clinton and Donald Trump. But the pharmaceutical industry will be focusing on another vote: Proposition 61, a California public referendum that could become the first initiative to truly draw blood from drug makers, which have largely refused to change their pricing habits despite an ongoing political firestorm over the issue.
Read Full Article »
